Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma

Official Title

A Phase II Study of Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma

Summary:

This is a multi-centre, open-label, Phase II clinical trial evaluating pembrolizumab in combination with carboplatin/paclitaxel as a treatment in unresectable locally advanced or metastatic melanoma.

Trial Description

Primary Outcome:

  • Overall Response Rate as assessed by RECIST 1.1 and immune-related Response Criteria
Secondary Outcome:
  • Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
  • Overall Survival
  • Progression Free Survival
  • Melanoma-associated serological markers by multiplexed array will be generated

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society